GLP-1 drugs may reduce alcohol use: systematic review of three clinical trials
A systematic review of three RCTs (n=48-151) found semaglutide and dulaglutide reduced alcohol use, while exenatide showed no significant effect on heavy drinking days.
Quick Facts
What This Study Found
Semaglutide reduced alcohol use; dulaglutide lowered intake in current drinkers; exenatide showed no significant effect on heavy drinking days. Three RCTs reviewed (n=48-151).
Key Numbers
Three RCTs reviewed (n = 48-151). Semaglutide reduced alcohol use. Dulaglutide lowered intake in current drinkers. Exenatide had no significant effect on heavy drinking days.
How They Did This
Systematic review of three randomized controlled trials (n=48-151) examining GLP-1 receptor agonists for alcohol use outcomes.
Why This Research Matters
Alcohol use disorder has few effective pharmacotherapies. If GLP-1 drugs—already widely prescribed for diabetes and obesity—also reduce alcohol consumption, they could address a major unmet medical need and benefit patients with overlapping conditions.
The Bigger Picture
GLP-1 receptors in the brain's reward centers may explain why these drugs reduce addictive behaviors. This systematic review adds controlled evidence to the growing observational data, potentially expanding GLP-1 drug indications into addiction medicine.
What This Study Doesn't Tell Us
Only three small RCTs available. Sample sizes were small (48-151). Not all GLP-1 drugs showed effects. Alcohol outcomes were not always primary endpoints. Larger, dedicated trials needed.
Questions This Raises
- ?Why does semaglutide appear more effective than exenatide for alcohol reduction?
- ?Are brain-penetrant GLP-1 drugs more effective for addiction applications?
- ?Would larger trials with alcohol use disorder as primary endpoint confirm these findings?
Trust & Context
- Key Stat:
- 2 of 3 drugs effective Semaglutide and dulaglutide reduced alcohol use in controlled trials, supporting the hypothesis that GLP-1 drugs affect brain reward pathways
- Evidence Grade:
- Systematic review of RCTs (good methodology) but limited by only 3 small trials with varying designs. Promising but preliminary evidence.
- Study Age:
- Published in 2025; summarizes the first controlled trial data on GLP-1 drugs and alcohol use.
- Original Title:
- GLP-1 receptor agonists and alcohol use disorder: a systematic review.
- Published In:
- Alcohol and alcoholism (Oxford, Oxfordshire), 61(1) (2025)
- Authors:
- Patel, Sheel, Blaney, Hanna, Nassar, Sarah, Singal, Ashwani K
- Database ID:
- RPEP-12982
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Can GLP-1 drugs help with alcohol addiction?
Early evidence suggests they might. This review found semaglutide and dulaglutide reduced alcohol use in small clinical trials. GLP-1 receptors exist in brain reward centers, which may explain why these drugs reduce the desire to drink. However, much larger studies are needed before these drugs can be recommended for alcohol use disorder.
Why might weight loss drugs reduce alcohol consumption?
GLP-1 drugs work partly by acting on brain reward pathways that control appetite and pleasure. These same pathways are involved in alcohol craving. By modifying reward signaling, GLP-1 drugs may reduce the pleasurable effects of alcohol and decrease the urge to drink.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12982APA
Patel, Sheel; Blaney, Hanna; Nassar, Sarah; Singal, Ashwani K. (2025). GLP-1 receptor agonists and alcohol use disorder: a systematic review.. Alcohol and alcoholism (Oxford, Oxfordshire), 61(1). https://doi.org/10.1093/alcalc/agaf069
MLA
Patel, Sheel, et al. "GLP-1 receptor agonists and alcohol use disorder: a systematic review.." Alcohol and alcoholism (Oxford, 2025. https://doi.org/10.1093/alcalc/agaf069
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonists and alcohol use disorder: a systemat..." RPEP-12982. Retrieved from https://rethinkpeptides.com/research/patel-2025-glp1-receptor-agonists-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.